Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?
| Autor: | Van Tine BA; Division of Medical Oncology, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.; Siteman Cancer Center, St. Louis, Missouri.; Department of Pediatric Hematology/Oncology, St Louis Children's Hospital, St. Louis, Missouri., Haarberg S; Division of Medical Oncology, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.; Siteman Cancer Center, St. Louis, Missouri. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 15; Vol. 30 (20), pp. 4552-4553. |
| DOI: | 10.1158/1078-0432.CCR-24-1628 |
| Abstrakt: | Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP-CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain. See related article by Schuetze et al., p. 4584. (©2024 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|